Orthostatic Hypotension, Reflex Syncope
Conditions
Keywords
tilt table test, valsalva
Brief summary
To characterize the impact of orthostatic hypotension (OH) and Vasovagal syncope on signals measured using a wearable Holter monitor in the clinic and ambulatory setting. To evaluate the relationship of signals measured from the Holter monitor with reported symptom severity of orthostatic intolerance per standard data collection, analysis, and questionnaires.
Detailed description
This is a non-randomized feasibility study that will enroll up to 40 participants that have undergone a previous autonomic reflex screen (ARS) assessment and were either diagnosed with OH or reflex syncope or considered to be control subjects for this study. A minimum of 20 subjects diagnosed with reflex syncope; a maximum of 15 subjects diagnosed with OH syncope and a maximum of 15 control subjects will be enrolled. There will be one in person study visit and a 21 day follow up period per subject.
Interventions
DEVICEWearable holter monitor
Participants will be fitted with a minimum of one wearable Holter monitor and up to 2 monitors, placed on the skin that measures physiologic signals. Participants will wear the monitor(s) for up approximately 21 days.
Sponsors
Boston Scientific Corporation
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Willing and capable to provide informed consent * Age 18 or above * Previously underwent a clinically indicated ARS assessment without complications (including deep breathing, Valsalva maneuver, and tilt table testing). * Previously diagnosed with OH, Vasovagal syncope, OR control subjects assessed as normal, based on the ARS assessment. Participant enrollment shall be based on the type of diagnosis. * Willing to complete all required study activities.
Exclusion criteria
* Currently enrolled in another clinical trial that might interfere with data collection. * Subject is pregnant or planning to become pregnant during the study * Active Implantable Medical Device, e.g. cardiac implantable electronic devices, bladder stimulators, diaphragm stimulators, implantable neuro stimulator, implantable active monitoring devices, implantable active drug administration devices, etc. * Have a prosthetic cardiac valve or previously underwent cardiac valve surgery. * Known allergy to materials used in the study (adhesive, ECG electrodes) * Diagnosed with syncope due to cardiologic causes. * Have had a myocardial infarction in the previous 90 days * Have been diagnosed with tachycardia that requires current medical treatment * Have any contraindications for exercise testing, tilt table test, Valsalva maneuver test or deep breathing test (judged by the study Principal Investigator)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Physiologic Signal Detection via wearable holter monitor | From enrollment through the 21 day follow up period | Blood pressure (mmHg) will be monitored in the clinic and ambulatory setting. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Physiologic Signal Detection via wearable holter monitor | From enrollment through the 21 day follow up | Heart rate (bpm) will be monitored in the clinic and ambulatory setting. |
Countries
United States
Contacts
CONTACTAshley M Jensen, Masters of Science
CONTACTMojgan Goftari, PhD
Outcome results
None listed